Stand Up To Cancer - standuptocancer.orgThis is where the end of cancer begins
   Please leave this field empty

Convergence Pancreatic Cancer

Share this:
Email

Like this page on Facebook

The SU2C–National Science Foundation- Lustgarten Foundation-V Foundation Pancreatic Cancer Convergence

Team Leader

  • Jeffrey Drebin, MD, PhD

    Team Leader
    Chairman of the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK)
    + Full Bio

About This Team’s Research

Pancreatic ductal adenocarcinoma (PDAC) is a frequent cause of cancer death in the United States; it currently is the fourth most common cause of cancer death and is expected to become the second most common cause of cancer death within the next five years.  Unlike virtually all other major cancers, pancreatic cancer is both increasing in incidence and has shown essentially no improvement in five-year survival over the past two decades.  The exceptional lethality of pancreatic cancer is multifactorial, resulting from an intrinsically aggressive biology, lack of effective means of early detection, and poor responsiveness to systemic chemotherapy.  Clearly novel approaches to this disease are needed. The proposed studies will build on previous findings to further explore potential immunotherapeutic approaches to pancreatic cancer. A consortium of three high volume pancreatic cancer centers (Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, and the Hospital of the University of Pennsylvania) will be organized to conduct a Phase I clinical trial. We have assembled a team of physicians, cancer immunobiologists, computational biophysicists, and engineers to better understand the unique immunological microenvironment of pancreatic cancer, develop the technologies needed to take advantage of therapeutic vulnerabilities, and to form a multi-institutional clinical consortium to readily implement these strategies to help change the course of this deadly disease.

Click here to see a full list of Dream Team members